NASDAQ$ABEO
Abeona Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Abeona Therapeutics reported a net loss of $12.029 million for Q1 2025, an improvement from the $31.578 million loss in Q1 2024, driven by a significant gain in the fair value of warrant and derivative liabilities.
Abeona Therapeutics Inc. reported a net loss of $12.029 million for the three months ended March 31, 2025, a substantial improvement compared to the $31.578 million net loss for the same period in 2024. This positive change was primarily due to a $7.245 million gain from the change in fair value of warrant and derivative liabilities, contrasting with a $17.301 million loss in the prior year. Operating expenses increased by 38% to $19.727 million, driven by higher research and development and general and administrative costs. The company's cash and cash equivalents stood at $15.936 million, with total assets at $99.364 million.
- Net loss significantly improved to $12.029 million in Q1 2025 from $31.578 million in Q1 2024, primarily due to a gain in fair value of warrant and derivative liabilities.
- Research and development expenses increased by 38% to $9.941 million, driven by increased headcount for manufacturing capacity scale-up and pre-clinical development work.
- General and administrative expenses rose by 37% to $9.786 million, mainly due to higher employee compensation and pre-commercial preparation costs.
- The company's liquidity position as of March 31, 2025, includes $84.5 million in cash resources, with additional proceeds from a subsequent common stock sale and a Priority Review Voucher sale expected to fund operations for at least the next 12 months.
Headline financials
Revenue & EPS history
Abeona Therapeutics · Revenue · Quarterly
$0
Forward guidance
Abeona Therapeutics expects its current cash resources, supplemented by recent and anticipated proceeds from common stock sales and the sale of a Priority Review Voucher, to be sufficient to fund operations for at least the next 12 months. The company anticipates continued operating losses until ZEVASKYN™ generates sufficient revenue to achieve profitability.
Tailwinds
- FDA approval of ZEVASKYN™ on April 28, 2025, as the first and only autologous cell-based gene therapy for RDEB.
- Awarded a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with FDA approval of ZEVASKYN™.
- Entered into a definitive asset purchase agreement to sell the PRV for gross proceeds of $155 million.
- Activation of the first Qualified Treatment Center (QTC) for ZEVASKYN™ at Ann & Robert H. Lurie Children's Hospital of Chicago.
- Extension of the loan principal monthly installments start date from May 1, 2025, to February 1, 2026, following FDA approval of ZEVASKYN™.
Headwinds
- Continued incurrence of significant operating losses and negative cash flows from operations since inception.
- Anticipation of continued losses until ZEVASKYN™ can provide sufficient revenue for profitability.
- Potential for dilution of existing investors' equity ownership if additional funds are raised through equity offerings.
- Risk of relinquishing valuable rights to technologies, future revenue streams, or product candidates if additional funds are raised through collaborations or licensing arrangements.
- Uncertainty regarding the ability to obtain additional financial resources or reduce operating expenses if required.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+6.6%
Avg return
30 days after
44%
27 / 62 earnings
Positive
+18.8%
Q3 2025
Best reaction
-28.9%
Q1 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -5.5% | — | |
| Q4 2025 | +6.1% | -10.1% | +8.7% | |
| Q3 2025 | +18.8% | +8.2% | +28.5% | |
| Q1 2025 | -4.2% | -2.8% | -8.1% | |
| Q4 2024 | -1.2% | -3.8% | -6.9% | |
| Q3 2024 | -3.9% | -3.4% | -3.4% | |
| Q2 2024 | +12.7% | +13.1% | +26.5% | |
| Q1 2024 | +9.5% | +6.0% | +8.8% | |
| Q4 2023 | -12.3% | -11.8% | -8.1% | |
| Q3 2023 | +3.9% | +2.4% | +15.4% | |
| Q2 2023 | +0.7% | +0.3% | +34.6% | |
| Q1 2023 | -7.2% | -5.3% | +32.8% | |
| Q4 2022 | +1.8% | +1.8% | +10.4% | |
| Q3 2022 | -8.0% | -8.0% | -32.3% | |
| Q2 2022 | +6.5% | +14.7% | -5.8% | |
| Q1 2022 | +12.5% | +0.0% | +6.3% | |
| Q4 2021 | +3.2% | +9.7% | -32.3% | |
| Q3 2021 | -5.4% | -19.6% | -43.5% | |
| Q2 2021 | -0.8% | +3.2% | +4.8% | |
| Q1 2021 | +6.5% | +6.5% | +9.0% | |
| Q4 2020 | -1.1% | -5.8% | -14.7% | |
| Q3 2020 | +11.7% | +24.3% | +41.7% | |
| Q2 2020 | +1.7% | -3.8% | -29.0% | |
| Q1 2020 | -7.2% | +29.1% | +16.3% | |
| Q4 2019 | +17.2% | +22.4% | +43.7% | |
| Q3 2019 | -6.4% | -6.8% | +60.2% | |
| Q2 2019 | +0.0% | +6.6% | +30.7% | |
| Q1 2019 | -8.2% | -3.0% | -29.3% | |
| Q4 2018 | -2.0% | -7.2% | +1.0% | |
| Q3 2018 | -22.0% | -24.1% | -13.6% | |
| Q2 2018 | -7.1% | -11.6% | -7.1% | |
| Q1 2018 | +10.9% | +11.4% | -13.8% | |
| Q4 2017 | -9.3% | -4.7% | +17.3% | |
| Q3 2017 | +6.6% | -2.6% | +9.3% | |
| Q2 2017 | +14.9% | +5.4% | +89.2% | |
| Q1 2017 | -1.6% | -1.6% | -20.8% | |
| Q4 2016 | +2.0% | +3.0% | +13.0% | |
| Q3 2016 | +5.7% | +18.0% | -15.6% | |
| Q2 2016 | +4.3% | +5.9% | +27.1% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | -5.0% | — | — | |
| Q3 2015 | +1.8% | — | — | |
| Q2 2015 | -3.9% | — | — | |
| Q1 2015 | -7.2% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q3 2014 | -8.5% | — | — | |
| Q1 2014 | +13.6% | — | — | |
| Q4 2013 | -10.3% | — | — | |
| Q2 2013 | -10.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -7.4% | — | — | |
| Q2 2012 | +6.5% | — | — | |
| Q1 2011 | -28.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +13.9% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q2 2011 | -4.4% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q3 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro